×
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
Nanchahal J., Ball C., Rombach I., Williams L., Kenealy N., Dakin H., O'Connor H., Davidson D., Werker P., Dutton SJ., Feldmann M., Lamb SE.
DOI
10.1016/s2665-9913(22)00093-5
Type
Journal
The Lancet Rheumatology
Publisher
Elsevier BV
Publication Date
04/2022